Latest News and Press Releases

Matisse Pharmaceuticals announces U.S. FDA clearance of the company’s Investigational New Drug (IND) application for isupartob sodium

New York, USA, May 12, 2026 (GLOBE NEWSWIRE) -- Sepsis Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight The sepsis...

NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering clinical-stage biotech company developing innovative therapies for inflammatory diseases, announces a...

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files...

Matisse Pharmaceuticals receives INN (International Non-proprietary Name) isupartob sodium from the WHO recognizing first-in-class drug status for M6229.

“Antimicrobial resistance is advancing silently, but its consequences are all too real"

Successful phase 1 with prolonged infusion duration could offer an effective solution for irreversibly stopping harmful inflammatory responses in sepsis.

Baton Rouge, LA, Sept. 17, 2025 (GLOBE NEWSWIRE) -- In alignment with Sepsis Awareness Month, members of the media are invited to attend a virtual press conference to learn more about sepsis and the...

UK MedTech company launches patient experience survey around overlooked & unreliable Urinary Tract Infection and prenatal screening diagnostics.

OXFORD, United Kingdom, July 16, 2025 (GLOBE NEWSWIRE) -- Vivid Dx, a precision diagnostics company transforming pathogen detection and antimicrobial resistance (AMR) testing, today announced the...